What Pandemic? Longitude Capital Closes a Big Fund

article image

COVID didn’t put a damper on the VC’s ability to close its fourth and largest fund, targeting transformative healthcare technologies.

In late March and early April, as COVID-19 ravaged California and much of the Northeast, concerns were raised in venture circles that the pandemic would have devastating effects on medtech investing in particular. As healthcare systems were overwhelmed caring for the high volume of patients, start-ups and their investors worried about a twin impact: a dramatic falloff in elective procedures and a shutdown of clinical trials. Six months later if there were any lingering concerns, the close of a new fund by Longitude Capital arguably puts most, if not all, of those concerns to rest.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: